EC Number   |
Application |
Reference |
|---|
  2.1.1.371 | medicine |
Nsd3 expression is increased in both acute myelogenous leukemia (AML) and acute lymphocytic leukemia (ALL) patients |
755933 |
| 2.1.1.371 | medicine |
NSD3 expression is reduced by isoproterenol stimuli both in vitro and in vivo. Overexpression of NSD3 attenuates isoproterenol-induced cardiomyocyte hypertrophy. Isoproterenol treatment decreases H3K27me2/3 modifications on the atrial natriuretic factor promoter by suppressing NSD3 and inhibits the association between NSD3 and bromodomain-containing protein BRD4, thus suppressing the BRD4-mediated H3K27ac modifications, which ultimately promote atrial natriuretic factor transcription and cardiomyocyte hypertrophy |
759195 |
| 2.1.1.371 | medicine |
silencing of NSD3 in osteosarcoma results in a marked decrease in the number of viable cancer cells, accompanied by increases in the cell population at the G2/M phase and the number of apoptotic cells. NSD3 negatively regulates a number of genes that are involved in the process of negative regulation of signal transduction as well as negative regulation of signaling and cell communication |
759879 |
| 2.1.1.371 | synthesis |
expression of NSDs via tagging with a human influenza hemagglutinin tag greatly improves the quality of the recombinant NSDs, resulting in more than 95% pure, stable, and active NSD-hemagglutinins, with an increase in production yield up to 22.4fold and up to 6.25 mg/l from LB Escherichia coli culture, and without further purification |
760083 |
